Scheduling of methylphenidate: Preventing misuse or impeding ADHD treatment adherence?
Renata Schoeman1, Sophia Weinberg1
1Stellenbosch Business School, Bellville, South Africa.
Summary
Rescheduling methylphenidate (MPH) for attention-deficit hyperactivity disorder (ADHD) in South Africa could improve treatment adherence and accessibility. Current regulations, however, act as a barrier to care and do not effectively prevent misuse.
Area of Science:
- Neuroscience
- Psychiatry
- Public Health
Background:
- Attention-deficit hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder with chronic implications if untreated.
- Poor medication adherence significantly impacts emotional, social, educational, and employment outcomes for individuals with ADHD.
- The current Schedule 6 classification of methylphenidate (MPH) in South Africa creates healthcare barriers and increases costs.
Purpose of the Study:
- To explore stakeholder perceptions on the impact of rescheduling MPH on ADHD treatment accessibility and adherence.
- To understand the potential benefits and risks associated with a regulatory shift in MPH scheduling.
Main Methods:
- Qualitative analysis of semi-structured interviews with 23 stakeholders involved in ADHD management in South Africa.
- Participants were recruited through professional networks.
Main Results:
- Six key themes emerged: adherence, accessibility, affordability, stigma, rescheduling of MPH, and risk mitigation.
- The scheduling of MPH plays a dual role, offering societal protection but also hindering access to care.
- Stakeholders expressed a positive outlook on rescheduling MPH, indicating potential for significant positive change.
Conclusions:
- The current Schedule 6 status of MPH is ineffective in preventing misuse and diversion while negatively impacting treatment adherence.
- Rescheduling MPH presents significant implications for the ADHD landscape in South Africa.
- Addressing stigma and removing structural barriers are crucial for improving ADHD outcomes, supported by a new treatment adherence framework.
Keywords:
attention deficit hyperactivity disorderbarriers to carediversionmethylphenidateregulatorystakeholder interviewstreatment adherenceMore Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
5.7K
09:16A General Method for Evaluating Deep Brain Stimulation Effects on Intravenous Methamphetamine Self-Administration
Published on: January 22, 2016
15.2K
Related Concept Videos
01:30Attention-Deficit/Hyperactivity Disorder
47
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by persistent inattention, hyperactivity, and impulsivity. It affects approximately 5-8% of children globally, with around 60-70% of cases persisting into adulthood. ADHD has significant implications for educational attainment, social interactions, and occupational success.
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
47
01:28Adrenergic Agonists: Mixed-Action Agents
678
Mixed-action adrenergic agonists, like ephedrine and pseudoephedrine, directly and indirectly affect adrenergic receptors. These agents stimulate adrenoceptors and indirectly release stored neurotransmitters, amplifying the adrenergic response.
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
Ephedrine and pseudoephedrine lack a catecholamine group, making them less susceptible to degradation by metabolic enzymes. They have increased oral bioavailability and lipophilicity, resulting in a longer duration of action. Their response is reduced by...
678
01:24Substance Use Disorders Affecting Sleep
161
Substance use disorders involve a pattern of using drugs more extensively than intended and continuing use despite harmful consequences. This includes legal substances like alcohol and nicotine, as well as illegal drugs. These disorders often involve both physical and psychological dependence, reflecting compulsive use of substances that significantly alter thoughts, feelings, and behaviors, contributing to a major public health issue.
Understanding the concepts of physical dependence,...
Understanding the concepts of physical dependence,...
161
01:28Drug Therapy
39
The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Antianxiety Medications
39
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
102
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
102
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
106
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
106